

The Relation between Glycated Haemoglobin and Fatty Liver in Non Diabetic Patient

Thesis

Submitted for Partial Fulfillment of Master Degree
in Internal Medicine

By

Hanaa Ahmed Hassan Ahmed
M.B.B.Ch.

Under Supervision of

Prof. Dr. Mohamed Ali Marie Makhoul

Professor of Internal Medicine
Faculty of Medicine- Ain Shams University

Prof. Dr. Magdy Galal El Din Abd El-Rahman

Professor of Internal Medicine
Faculty of Medicine- Ain Shams University

Dr. Ahmed Elsaady Khial

Lecturer of Internal Medicine
Faculty of Medicine- Ain Shams University

**Faculty of Medicine
Ain shams University
2014**



Above and before all, I would like to kneel thank to ALLAH the all mighty, the most merciful for the support, guidance and mercy. He grants me throughout my life.

I would like to express my deep gratitude and appreciation to **Prof. Dr. Mohamed Ali Mari Makhlouf**, Professor of Internal Medicine- Ain Shams University, for his kind supervision and support.

Special thanks to **Prof. Dr. Magdy Galal El Din Abd El-Rahman**, Professor of Internal Medicine- Ain Shams University, for his positive attitude toward my work, great support and continuous guidance. Also, my thanks to **Dr. Ahmed Elsaady Khial**, Lecturer of Internal Medicine- Ain Shams University.

I can't find the appropriate words to express how much I'm grateful to my **mother Fatima, father Ahmed, sisters, brothers**, all my family and my friends. There is nothing I can offer to them could be comparable to anything they had offered to me.

Special thanks to my husband **Mohamed** for his continuous support.

God send peace upon soul of my mother

Hanaa Ahmed Hassan





**I dedicate this work to the
soul of my **mother**, my **father**
my **husband** and my **son**.**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

«قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا
مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ
الْحَكِيمُ»

صدق الله العظيم

سورة البقرة آية (٣٢)

Contents

List of Abbreviations	I
List of Tables	V
List of Figures	VI
Introduction	1
Aim of the Work	6
Review of Literature	
- Chapter (1): History and Definition of NAFLD	5
- Chapter (2): Epidemiology of NAFLD	12
- Chapter (3): Etiology of NAFLD	15
- Chapter (4): NAFLD pathogenesis	26
- Chapter (5): Natural history and Complication of NAFLD	40
- Chapter (6): Diagnosis of NAFLD.....	49
- Chapter (7): Management of NALFLD.....	75
Subjects and Methods	99
Results	102
Discussion	126
Summary and Conclusion	133
Recommendations	136
References	137
Arabic Summary	—

List of Abbreviations

Abb.	Meaning
A1C	Glycated haemoglobin
AAR	AST/ALT ratio
AASLD	American Association for the Study of Liver Diseases
ACEIs	Angiotensin converting enzyme inhibitors
ALT	Alanine aminotransferase
AMPK	AMP dependent protein kinase
Apaf-1	Apoptotic-protein activation factor-1
apo B	Apolipoprotein B
APRI	AST-to-platelet ratio index
ARBs	Angiotensin receptors blockers
ART	Anti-retroviral therapy
AST	Aspartate aminotransferase
AUROC	Area-under-the-receiver-operating-characteristic curves
BMI	Body mass index
BP	Blood pressure
BSG	British Society of Gastroenterology
CC	Cryptogenic cirrhosis
CHD	Coronary heart disease
CI	Confidence interval
CK-18	Cytokeratin-18
CRP	C reactive protein
CT	Computed tomography
CVD	Cardiovascular disease

Abb.	Meaning
FFA	Free fatty acids
FLI	Fatty liver index
FRAX tool	The Fracture Risk Assessment Tool
GGT	Gamma-glutamyl transferase
GLP-1	Glucagon-like peptide-1
GSH-Px	Glutathione peroxidase
HA	Hyaluronic acid
HbA1C	Glycated haemoglobin
HBc-Ab	Hepatitis B core antibody
HBs.Ag	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HCV-Ab	Hepatitis C virus antibody
HDL	High density lipoprotein
HIV	Human immunodeficiency virus
HMG-COA	3-hydroxy-3-methyl-glutaryl-CoA reductase
IKB	Inhibitory KB
IKK	Inhibitory –KB Kinase
IL	Interleukin
IR	Insulin resistance
LAP	Lipid accumulation product
LB	Liver biopsy
LCTs	Liver chemistry tests
LDL	Low-density lipoprotein
LFC	Liver fat content
LFTs	Liver functions tests

Abb.	Meaning
LKB1-mediated AMPK	LKB1 gene mediate activation of hepatic AMP-protein kinase
LPS	Lipopolysaccharides
MAPK	Mitogen activated protein kinase
MRI	Magnetic resonance imaging
MRS	Magnetic Resonance Spectroscopy
MTP	Microsomal triglyceride transfer protein
NAFL	Nonalcoholic fatty liver
NAFLD	Non-alcoholic fatty liver disease
NAS	NAFLD Activity Score
NASH	Non-alcoholic steatohepatitis
NEFAs	Nonsterified fatty acids
NF-KB	Nuclear factor -KB
NFS	NAFLD fibrosis score
OR	Odd ratio
OSA	Obstructive sleep apnoea
PAI-1	Plasminogen activator inhibitor-1
PPAR	Peroxisome proliferator-activated receptor gamma
PUFAs	Polyunsaturated fatty acids
RAS	Renin-angiotensin system
RCT	Randomised control trial
ROS	Reactive oxygen species
SNP	Single nucleotide polymorphism
SREBP	Sterol regulatory element binding protein
T2DM	Type 2 diabetes mellitus

Abb.	Meaning
TG	Triglycerides
TGF B	Transforming growth factor-beta
TNF α	Tumor necrosis factor alpha
TPN	Total parental nutrition
TRX	Thioredoxin
TZDs	Thiazolidinediones
UDCA	Ursodeoxy cholic acid
US	Ultrasonography
VAI	Visceral adiposity index
VLDL	Very low density lipoprotein
WAT	White adipose tissue
WC	Waist circumference

List of Tables

Table	Title	Page
1	Nonalcoholic Fatty Liver Disease and related definitions	11
2	Causes of nonalcoholic fatty liver Disease	19
3	Indications for Liver Biopsy in Patients with NAFLD	73
4	Interventions for treatment of NAFLD	77
5	Summarises the treatment of type 2 diabetes and the metabolic syndrome in NAFLD	90
6	Summarises the management of the metabolic syndrome	93
7	Managing the complications of cirrhosis	98
8	Glycated haemoglobin in cases group	103
9	Glycated haemoglobin in control group	104
10	Baseline characteristics of the sample	105
11	Comparison between cases and controls in different variables	109
12	Correlation between HbA1c and (liver enzymes, total cholesterol, fasting blood glucose and BMI)	116
13	Correlation between presence of absence of fatty liver and some variables	124

List of Figures

Figure	Title	Page
1	Development of nonalcoholic hepatic steatosis	28
2	Natural history of nonalcoholic fatty liver disease	40
3	Mechanisms of NASH-Induced Hepatocarcinogenesis	44
4	Possible mechanisms leading to cardiac and arrhythmogenic complications in non-alcoholic fatty liver disease	48
5	Hepatic steatosis ultrasonography image	64
6	Grades of fatty liver on visual analysis	65
7	CT for detection of liver fat	66
8	Shear wave elastography	68
9	Liver biopsy with Mallory staining for fibrosis	70
10	Histologic features of fibrosis in nonalcoholic steatohepatitis	71
11	Histologic features of necrotic inflammation in NASH	71
12	A proposed algorithm for the decision to obtain a liver biopsy	74
13	Management strategies in non-alcoholic fatty liver disease	76
14	Sex of studied cases	106
15	BMI categories of studied group	106
16	SGOT of studied group	107

Figure	Title	Page
17	SGPT of studied group	107
18	GGT of studied group	108
19	Total cholesterol of studied group	108
20	Sex in cases group	110
21	Sex in control group	110
22	BMI categories in cases group	111
23	BMI categories in control group	111
24	SGOT in cases group	112
25	SGOT in control group	112
26	SGPT in cases group	113
27	SGPT in control group	113
28	GGT in cases group	114
29	GGT in control group	114
30	Total cholesterol in cases group	115
31	Total cholesterol in control group	115
32	Correlation between SGOT and HbA1c in cases group	117
33	Correlation between SGOT and HbA1c in control group	117
34	Correlation between SGPT and HbA1c in cases group	118
35	Correlation between SGPT and HbA1c in control group	118
36	Correlation between GGT and HbA1c in cases group	119

Figure	Title	Page
37	Correlation between GGT and HbA1c in control group	119
38	Correlation between total cholesterol and HbA1c in cases group	120
39	Correlation between total cholesterol and HbA1c in control group	120
40	Correlation between fasting blood glucose and HbA1c in cases group	121
41	Correlation between fasting blood glucose and HbA1c in control group	121
42	Correlation between BMI and HbA1c in cases group	122
43	Correlation between BMI and HbA1c in control group	123

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is an increasingly common cause of chronic liver disease worldwide. It comprises a disease spectrum ranging from benign hepatic steatosis to non-alcoholic steatohepatitis with inflammation (NASH) and liver cirrhosis. Although simple steatosis appears to be benign, NASH can progress to cirrhosis with its resultant complications, including hepatocellular carcinoma (HCC). It is increasingly recognised that NASH accounts for a significant proportion of “cryptogenic” or “idiopathic” cirrhosis (**Tan, 2010**).

Nonalcoholic fatty liver disease (NAFLD) has gained recognition worldwide as a common chronic liver disease and as a cofactor in other diseases. The subclinical nature of the disease has lead to increased efforts to achieve its diagnosis and to prevent its potential progression to nonalcoholic steatohepatitis (NASH), liver cirrhosis and hepatocellular carcinoma (**Powell et al., 2006**).

Non alcoholic fatty liver disease is characterised by fatty infiltration of the liver, mostly in the form of triglycerides, which exceed 5% of liver weight (**Angulo et al., 2007**).

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world (it

affects 30% of the general adult population) (**Musso et al., 2010**).

The NAFLD is an umbrella term for a group of diseases defined by a hepatic fat infiltration >5% hepatocyte, in the absence of excessive alcohol intake, defined by two standard drinks (20 g ethanol) daily for men and one standard drink (10 g ethanol) daily for women (**Durazzo et al., 2012**).

The NAFLD encompasses a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), defined by steatosis, hepatocellular damage, and lobular inflammation in the individuals without significant alcohol consumption and negative viral, congenital, and autoimmune liver disease markers (**Farrell et al., 2005**).

While steatosis does not carry the risk of progressive liver disease, patients with NASH are at risk of developing cirrhosis (20–30% of patients) (**Farrell and Larter, 2006**).

NASH may progress to decompensated liver disease and result in liver failure. Furthermore, NASH confers an increased risk of cardiovascular disease (CVD) and diabetes both directly and through its association with other cardiometabolic abnormalities, including obesity and metabolic syndrome (**Ghouri et al., 2010**).